Top

Clinical Rheumatology

Published in:

01-03-2019 | Original Article

Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life

Authors: Hania S Zayed, Basma M Medhat, Esraa M Seif

Published in: Clinical Rheumatology | Issue 3/2019

Abstract

Introduction/objectives

Despite its importance, adherence to treatment has not been sufficiently studied in Behçet’s disease (BD). The aim of this study was to evaluate medication adherence in BD using the Compliance Questionnaire of Rheumatology (CQR) and factors potentially affecting it.

Method

This cross-sectional study included 67 consecutive BD patients including 57 (85%) males with a mean age of 35.1 ± 9.27 years and mean disease duration of 129 ± 91 months. The cumulative clinical manifestations, the Behçet’s Disease Current Activity Form (BDCAF) score, and the Vasculitis Damage Index (VDI) were recorded. The CQR, Socioeconomic Status Questionnaire for Health Research in Egypt (SES), the Beliefs about Medication Questionnaire (BMQ), and the Short Form 36 (SF-36) quality of life assessment questionnaire were administered to the patients. Linear regression analysis was done to determine independent predictors of CQR.

Results

The mean BDCAF score was 3.27 ± 3.54 and the VDI was 3.36 ± 2.21. The mean CQR score was 69.2 ± 11.79. The CQR score varied significantly among different health sources (p = 0.02), with no relationship detected with other sociodemographic characteristics, nor with clinical characteristics or the SF-36. Among the investigated medications’ complexities, severity of side effects showed significantly different CQR scores (p = 0.004), and a weak positive correlation between medications’ numbers and the CQR was detected. Predictors for higher CQR scores included the necessity beliefs score of the BMQ (β = 1.1, p < 0.001); whereas, predictors for lower CQR scores were the harm and concern BMQ subscales ((β = − 1.5, p = 0.004) and (β = − 0.72, p = 0.032), respectively).

Conclusions

Beliefs about medications were the only predictor for adherence in our cohort.

Behcet H (1937) Uber rezidivierende, aphthose durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalian. Dermatol Wochenschr 105:1152–1157

Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632. https://doi.org/10.1111/1346-8138.13381 CrossRefPubMed

Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, Yazici H (2014) Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol 41(3):599–612. https://doi.org/10.3899/jrheum.131249 CrossRefPubMedPubMedCentral

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health J 11(1):44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x CrossRef

Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32(11):983–1028. https://doi.org/10.1007/s12325-015-0256-7 CrossRefPubMedPubMedCentral

Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt BJ, van de Laar M (2016) Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskelet. Disord 17(1):442. https://doi.org/10.1186/s12891-016-1289-z CrossRef

Khabbazi A, Karkon Shayan F, Ghojazadeh M, Kavandi H, Hajialiloo M, Esalat Manesh K, Kolahi S (2017) Adherence to treatment in patients with Behcet’s disease. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.13109

de Achaval S, Suarez-Almazor ME (2010) Improving treatment adherence in patients with rheumatologic disease. J Musculoskelet Med 27(10):1691476PubMedPubMedCentral

Kim D, Choi JY, Cho SK, Choi CB, Bang SY, Cha HS, Choe JY, Chung WT, Hong SJ, Kim TH, Kim TJ (2018) Prevalence and associated factors for non-adherence in patients with rheumatoid arthritis. J Rheum Dis 25(1):47–57. https://doi.org/10.4078/jrd.2018.25.1.47 CrossRef

10.

Arturi P, Schneeberger EE, Sommerfleck F, Buschiazzo E, Ledesma C, Cocco JA, Citera G (2013) Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol 32(7):1007–1015. https://doi.org/10.1007/s10067-013-2221-7 CrossRefPubMed

11.

Ragab OM, Zayed HS, Abdelaleem EA, Girgis AE (2017) Effect of early treatment with disease-modifying anti-rheumatic drugs and treatment adherence on disease outcome in rheumatoid arthritis patients. Egypt Rheumatologist 39(2):69–74. https://doi.org/10.1016/j.ejr.2016.11.004 CrossRef

12.

Prados-Moreno S, Sabio JM, Pérez-Mármol JM, Navarrete-Navarrete N, Peralta-Ramírez MI (2017) Adherence to treatment in patients with systemic lupus erythematosus. Med Clín (English Edition) 150:8–15. https://doi.org/10.1016/j.medcle.2017.11.023 CrossRef

13.

Prudente LR, Diniz JS, Ferreira TXAM, Lima DM, Silva NA, Saraiva G, Silveira EA, Dewulf NLS, Amaral RG (2016) Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Prefer Adherence 10:863–870. https://doi.org/10.2147/PPA.S79451 CrossRefPubMedPubMedCentral

14.

Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA (2017) Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res 69(11):1706–1713. https://doi.org/10.1002/acr.23191 CrossRef

15.

Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T (2017) Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Preference Adherence 11:1591–1601. https://doi.org/10.2147/PPA.S144624 CrossRefPubMed

16.

Bruce IN, Gladman DD, Urowitz MB (2000) Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 13:406–408. https://doi.org/10.1002/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2 CrossRefPubMed

17.

Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, Katz P (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240–246. https://doi.org/10.1002/art.24236 CrossRefPubMedPubMedCentral

18.

Wan GJ, Kozma CM, Slaton TL, Olson WH, Feagan BG (2014) Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy. J Med Econ 17(6):384–393. https://doi.org/10.3111/13696998.2014.909436 CrossRefPubMed

19.

Cinar M, Cinar FI, Acikel C, Yilmaz S, Çakar M, Horne R, Simsek I (2016) Reliability and validity of the Turkish translation of the beliefs about medicines questionnaire (BMQ-T) in patients with Behçet’s disease. Clin Exp Rheumatol 34(6):S46–S51PubMed

20.

Cinar M, Cinar FI, Yilmaz S, Acikel C, Cakar M, Simsek I (2016) SAT0359 evaluation of medication compliance in Behcet’s disease. Ann Rheum Dis 75:797. https://doi.org/10.1136/annrheumdis-2016-eular.5266 CrossRef

21.

Mumcu G, Alibaz-Öner F, Öner SY, Özen G, Atagündüz P, İnanç N, Köksal L, Ergun T, Direskeneli H (2017) Oral ulcer activity in Behcet’s disease: poor medication adherence is an underestimated risk factor. Eur J Rheumatol 4(2):109–112. https://doi.org/10.5152/eurjrheum.2017.160094 CrossRefPubMedPubMedCentral

22.

de Klerk E, van der Heijde D, van der Tempel H, van der Linden S (1999) Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 26(12):2635–2641PubMed

23.

van den Bemt BJF, Zwikker HE, van den Ende CHM (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8(4):337–351CrossRefPubMed

24.

Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS et al (2014) International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. https://doi.org/10.1111/jdv.12107 CrossRef

25.

El-Gilany A, El-Wehady A, El-Wasify M (2012) Updating and validation of the socioeconomic status scale for health research in Egypt/Mise à jour et validation d’une échelle du statut socioéconomique pour la recherche en santé en Égypte. East Mediterr Health J 18(9):962–968CrossRefPubMed

26.

Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatol 38(8):728–733. https://doi.org/10.1093/rheumatology/38.8.728 CrossRef

27.

Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380. https://doi.org/10.1002/art.1780400222 CrossRefPubMed

28.

Davydov VF (1980) Types of drug side effects and their classification. Farmakol Toksikol 43(6):652–661PubMed

29.

Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-Item Health Survey 1.0. Health Econ 2(3):217–227. https://doi.org/10.1002/hec.4730020305 CrossRefPubMed

30.

Horne R (1999) Patients’ beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 47(6):491–495. https://doi.org/10.1016/S0022-3999(99)00058-6 CrossRefPubMed

31.

Alsous M, Alhalaiqa F, Abu Farha R, Abdel Jalil M, McElnay J, Horne R (2017) Reliability and validity of Arabic translation of Medication Adherence Report Scale (MARS) and Beliefs about Medication Questionnaire (BMQ)-specific for use in children and their parents. PloS One 12(2):e0171863. https://doi.org/10.1371/journal.pone.0171863 CrossRefPubMedPubMedCentral

32.

Gottlieb H (2000) Medication nonadherence: finding solutions to a costly medical problem CME. Drug Benefit Trends 12(6):57–62

33.

Jimmy B, Jose J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26(3):155–159. https://doi.org/10.5001/omj.2011.38 CrossRefPubMedPubMedCentral

34.

Joplin S, van der Zwan R, Joshua F, Wong PK (2015) Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015:1–10. https://doi.org/10.1155/2015/150658 CrossRef

35.

de Klerk E, van der Heijde D, Landewé R, van der Tempel H, van der Linden S (2003) The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 30(11):2469–2475PubMed

36.

Treharne G, Lyons A, Kitas G (2004) Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychology, health & medicine 9(3):337–349. https://doi.org/10.1080/13548500410001721909 CrossRef

37.

van den Bemt BJF, van den Hoogen FHJ, Benraad B, Hekster YA, van Riel PLCM, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36(10):2164–2170. https://doi.org/10.3899/jrheum.081204 CrossRefPubMed

38.

Hromadkova L, Soukup T, Vlcek J (2015) Quality of life and drug compliance: their interrelationship in rheumatic patients. J Eval Clin Pract 21(5):919–924. https://doi.org/10.1111/jep.12399 CrossRefPubMed

39.

Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54(10):1780–1791. https://doi.org/10.1093/rheumatology/kev105 CrossRefPubMed

40.

de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K (2010) Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int 30(11):1441–1448. https://doi.org/10.1007/s00296-009-1160-8 CrossRefPubMed

41.

Kuipers JG, Koller M, Zeman F, Mueller K, Rueffer JU (2017) THU0115 disability (HAQ) and quality of life (SF-12) as related to adherence and health literacy in patients with rheumatoid arthritis. Ann Rheum Dis 76:244. https://doi.org/10.1136/annrheumdis-2017-eular.5415 CrossRef

42.

Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296–1310. https://doi.org/10.1016/S0149-2918(01)80109-0 CrossRefPubMed

43.

Müller R, Kallikorm R, Põlluste K, Lember M (2012) Compliance with treatment of rheumatoid arthritis. Rheumatol Int 32(10):3131–3135. https://doi.org/10.1007/s00296-011-2162-x CrossRefPubMed

Title: Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life
Authors: Hania S Zayed
Basma M Medhat
Esraa M Seif
Publication date: 01-03-2019
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 3/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4344-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life

Abstract

Introduction/objectives

Method

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction/objectives

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors

Treating psoriatic arthritis to target: discordance between physicians and patients’ assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort

Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis

Correction to: Evaluation of the effects of miRNAs in familial Mediterranean fever

Autoantibody and metalloproteinase activity in early arthritis

Acknowledgement to referees 2018

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page